R-verapamil - AGI Therapeutics

Drug Profile

R-verapamil - AGI Therapeutics

Alternative Names: AGI-003; Arverapamil - AGI Therapeutics; Rezular

Latest Information Update: 30 Sep 2009

Price : $50

At a glance

  • Originator AGI Therapeutics
  • Class Antiarrhythmics; Antihypertensives; Antineoplastics; Irritable bowel syndrome therapies; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Melatonin receptor modulators; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 22 Sep 2009 Final adverse events data from a Phase-III trial, ARDIS-1, in Diarrhoea-predominant irritable bowel syndrome released by AGI Therapeutics
  • 15 May 2009 Discontinued - Phase-III for Irritable bowel syndrome in South America (PO)
  • 15 May 2009 Discontinued - Phase-III for Irritable bowel syndrome in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top